Precision BioSciences, Inc. (DTIL), Tuesday announced that the U.S. Food and Drug Administration has granted Fast Track designation for PBGENE-HBV, a first-in-class gene editing therapy designed to eliminate the root cause of chronic hepatitis B.
Currently, the company is evaluating PBGENE-HBV in the ongoing global Phase 1 ELIMINATE-B trial, with clinical investigation in the United States, Moldova, Hong Kong, New Zealand, and the United Kingdom.
The clinical stage gene editing company anticipates to share updates on the full low-dose cohort, including multiple dose administrations, and data from higher dose levels throughout 2025.
In the pre-market hours, Precision's stock is trading at $4.77, up 6.95 percent on the Nasdaq.
For comments and feedback: editorial@rttnews.com